- Home
- KPRX vs BBGI Comparison
KPRX vs BBGI Comparison
Compare KPRX & BBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- BBGI
- Stock Information
- Founded
- KPRX 1998
- BBGI 1961
- Country
- KPRX United States
- BBGI United States
- Employees
- KPRX N/A
- BBGI N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BBGI Broadcasting
- Sector
- KPRX Health Care
- BBGI Consumer Discretionary
- Exchange
- KPRX Nasdaq
- BBGI Nasdaq
- Market Cap
- KPRX 12.0M
- BBGI 13.2M
- IPO Year
- KPRX N/A
- BBGI 2000
- Fundamental
- Price
- KPRX $3.47
- BBGI $7.81
- Analyst Decision
- KPRX Strong Buy
- BBGI
- Analyst Count
- KPRX 1
- BBGI 0
- Target Price
- KPRX $10.00
- BBGI N/A
- AVG Volume (30 Days)
- KPRX 46.3K
- BBGI 3.1K
- Earning Date
- KPRX 03-24-2025
- BBGI 03-04-2025
- Dividend Yield
- KPRX N/A
- BBGI N/A
- EPS Growth
- KPRX N/A
- BBGI N/A
- EPS
- KPRX 1.69
- BBGI 1.69
- Revenue
- KPRX $16,020,000.00
- BBGI $238,754,777.00
- Revenue This Year
- KPRX N/A
- BBGI $2.55
- Revenue Next Year
- KPRX N/A
- BBGI N/A
- P/E Ratio
- KPRX $2.05
- BBGI $4.63
- Revenue Growth
- KPRX N/A
- BBGI N/A
- 52 Week Low
- KPRX $3.00
- BBGI $7.60
- 52 Week High
- KPRX $6.75
- BBGI $18.40
- Technical
- Relative Strength Index (RSI)
- KPRX 44.69
- BBGI 40.68
- Support Level
- KPRX $3.40
- BBGI $7.77
- Resistance Level
- KPRX $3.75
- BBGI $8.10
- Average True Range (ATR)
- KPRX 0.22
- BBGI 0.25
- MACD
- KPRX -0.03
- BBGI 0.03
- Stochastic Oscillator
- KPRX 37.65
- BBGI 13.16
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About BBGI Beasley Broadcast Group Inc.
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The Company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. The Company owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The Company currently operates three operating segments Audio, Digital and esports.